BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 23595598)

  • 21. Correlation between GLA variants and alpha-Galactosidase A profile in dried blood spot: an observational study in Brazilian patients.
    Varela P; Mastroianni Kirsztajn G; Motta FL; Martin RP; Turaça LT; Ferrer HLF; Gomes CP; Nicolicht P; Mara Marins M; Pessoa JG; Braga MC; D'Almeida V; Martins AM; Pesquero JB
    Orphanet J Rare Dis; 2020 Jan; 15(1):30. PubMed ID: 31996269
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of infants at risk for developing Fabry, Pompe, or mucopolysaccharidosis-I from newborn blood spots by tandem mass spectrometry.
    Scott CR; Elliott S; Buroker N; Thomas LI; Keutzer J; Glass M; Gelb MH; Turecek F
    J Pediatr; 2013 Aug; 163(2):498-503. PubMed ID: 23465405
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fabry disease screening in high-risk populations in Japan: a nationwide study.
    Yoshida S; Kido J; Sawada T; Momosaki K; Sugawara K; Matsumoto S; Endo F; Nakamura K
    Orphanet J Rare Dis; 2020 Aug; 15(1):220. PubMed ID: 32843101
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lysosomal storage disorder 4+1 multiplex assay for newborn screening using tandem mass spectrometry: application to a small-scale population study for five lysosomal storage disorders.
    Orsini JJ; Martin MM; Showers AL; Bodamer OA; Zhang XK; Gelb MH; Caggana M
    Clin Chim Acta; 2012 Aug; 413(15-16):1270-3. PubMed ID: 22548856
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Detection of novel Fabry disease-associated pathogenic variants in Japanese patients by newborn and high-risk screening.
    Sawada T; Kido J; Sugawara K; Matsumoto S; Takada F; Tsuboi K; Ohtake A; Endo F; Nakamura K
    Mol Genet Genomic Med; 2020 Nov; 8(11):e1502. PubMed ID: 33016649
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fabry disease: incidence of the common later-onset α-galactosidase A IVS4+919G→A mutation in Taiwanese newborns--superiority of DNA-based to enzyme-based newborn screening for common mutations.
    Chien YH; Lee NC; Chiang SC; Desnick RJ; Hwu WL
    Mol Med; 2012 Jul; 18(1):780-4. PubMed ID: 22437327
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fabry disease in patients with end-stage renal failure: the potential benefits of screening.
    Bekri S; Enica A; Ghafari T; Plaza G; Champenois I; Choukroun G; Unwin R; Jaeger P
    Nephron Clin Pract; 2005; 101(1):c33-8. PubMed ID: 15886492
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Detecting multiple lysosomal storage diseases by tandem mass spectrometry--a national newborn screening program in Taiwan.
    Liao HC; Chiang CC; Niu DM; Wang CH; Kao SM; Tsai FJ; Huang YH; Liu HC; Huang CK; Gao HJ; Yang CF; Chan MJ; Lin WD; Chen YJ
    Clin Chim Acta; 2014 Apr; 431():80-6. PubMed ID: 24513544
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Detection of α-Galactosidase A Reaction in Samples Extracted from Dried Blood Spots Using Ion-Sensitive Field Effect Transistors.
    Kuznetsov A; Sheshil A; Smolin E; Grudtsov V; Ryazantsev D; Shustinskiy M; Tikhonova T; Kitiashvili I; Vechorko V; Komarova N
    Sensors (Basel); 2024 Jun; 24(11):. PubMed ID: 38894470
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Usefulness of lyso-globotriaosylsphingosine in dried blood spots in the differential diagnosis between multiple sclerosis and Anderson-Fabry's disease.
    Olivera S; Iñiguez C; García-Fernández L; Sierra JL; Camón AM; Menao S; Torralba MÁ
    Mult Scler Relat Disord; 2020 Feb; 38():101466. PubMed ID: 31715500
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fabry disease: a new approach for the screening of females in high-risk groups.
    Pasqualim G; Simon L; Sperb-Ludwig F; Burin MG; Michelin-Tirelli K; Giugliani R; Matte U
    Clin Biochem; 2014 May; 47(7-8):657-62. PubMed ID: 24582695
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fabry disease: identification of novel alpha-galactosidase A mutations and molecular carrier detection by use of fluorescent chemical cleavage of mismatches.
    Germain DP; Poenaru L
    Biochem Biophys Res Commun; 1999 Apr; 257(3):708-13. PubMed ID: 10208848
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunoquantification of alpha-galactosidase: evaluation for the diagnosis of Fabry disease.
    Fuller M; Lovejoy M; Brooks DA; Harkin ML; Hopwood JJ; Meikle PJ
    Clin Chem; 2004 Nov; 50(11):1979-85. PubMed ID: 15364892
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fabry disease: polymorphic haplotypes and a novel missense mutation in the GLA gene.
    Ferri L; Guido C; la Marca G; Malvagia S; Cavicchi C; Fiumara A; Barone R; Parini R; Antuzzi D; Feliciani C; Zampetti A; Manna R; Giglio S; Della Valle CM; Wu X; Valenzano KJ; Benjamin R; Donati MA; Guerrini R; Genuardi M; Morrone A
    Clin Genet; 2012 Mar; 81(3):224-33. PubMed ID: 21517827
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevalence of Fabry disease and GLA variants in young patients with acute stroke: The challenge to widen the screening. The Fabry-Stroke Italian Registry.
    Romani I; Sarti C; Nencini P; Pracucci G; Zedde M; Cianci V; Nucera A; Moller J; Orsucci D; Toni D; Palumbo P; Casella C; Pinto V; Barbarini L; Bella R; Scoditti U; Ragno M; Mezzapesa DM; Tassi R; Volpi G; Diomedi M; Bigliardi G; Cavallini AM; Chiti A; Ricci S; Cecconi E; Linoli G; Sacco S; Rasura M; Giordano A; Bonetti B; Melis M; Cariddi LP; Dossi RC; Grisendi I; Aguglia U; Di Ruzza MR; Melis M; Sbardella E; Vista M; Valenti R; Musolino RF; Passarella B; Direnzo V; Pennisi G; Genovese A; Di Marzio F; Sgobio R; Acampa M; Nannucci S; Dagostino F; Dell'Acqua ML; Cuzzoni MG; Picchioni A; Calchetti B; Notturno F; Di Lisi F; Forlivesi S; Delodovici ML; Buechner SC; Biagini S; Accavone D; Manna R; Morrone A; Inzitari D
    J Neurol Sci; 2024 Feb; 457():122905. PubMed ID: 38295534
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A comprehensive testing algorithm for the diagnosis of Fabry disease in males and females.
    Stiles AR; Zhang H; Dai J; McCaw P; Beasley J; Rehder C; Koeberl DD; McDonald M; Bali DS; Young SP
    Mol Genet Metab; 2020 Jul; 130(3):209-214. PubMed ID: 32418857
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A systematic review on screening for Fabry disease: prevalence of individuals with genetic variants of unknown significance.
    van der Tol L; Smid BE; Poorthuis BJ; Biegstraaten M; Deprez RH; Linthorst GE; Hollak CE
    J Med Genet; 2014 Jan; 51(1):1-9. PubMed ID: 23922385
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeted Screening of Fabry Disease in Male Hemodialysis Patients in Brazil Highlights Importance of Family Screening.
    Silva CA; Barreto FC; Dos Reis MA; Moura Junior JA; Cruz CM
    Nephron; 2016; 134(4):221-230. PubMed ID: 27576502
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multicenter evaluation of use of dried blood spot compared to conventional plasma in measurements of globotriaosylsphingosine (LysoGb3) concentration in 104 Fabry patients.
    Malvagia S; Ferri L; Della Bona M; Borsini W; Cirami CL; Dervishi E; Feriozzi S; Gasperini S; Motta S; Mignani R; Trezzi B; Pieruzzi F; Morrone A; Daniotti M; Donati MA; la Marca G
    Clin Chem Lab Med; 2021 Aug; 59(9):1516-1526. PubMed ID: 33915609
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Plasma globotriaosylsphingosine in relation to phenotypes of Fabry disease.
    Smid BE; van der Tol L; Biegstraaten M; Linthorst GE; Hollak CE; Poorthuis BJ
    J Med Genet; 2015 Apr; 52(4):262-8. PubMed ID: 25596309
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.